MA43977A - Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave - Google Patents

Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave

Info

Publication number
MA43977A
MA43977A MA043977A MA43977A MA43977A MA 43977 A MA43977 A MA 43977A MA 043977 A MA043977 A MA 043977A MA 43977 A MA43977 A MA 43977A MA 43977 A MA43977 A MA 43977A
Authority
MA
Morocco
Prior art keywords
treatment
cancer patients
kidney failure
severe kidney
severe
Prior art date
Application number
MA043977A
Other languages
English (en)
Inventor
Kenichiro Yoshida
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59501005&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA43977A publication Critical patent/MA43977A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA043977A 2016-02-05 2017-02-03 Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave MA43977A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662291799P 2016-02-05 2016-02-05

Publications (1)

Publication Number Publication Date
MA43977A true MA43977A (fr) 2018-12-12

Family

ID=59501005

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043977A MA43977A (fr) 2016-02-05 2017-02-03 Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave

Country Status (12)

Country Link
US (4) US10456399B2 (fr)
EP (1) EP3412295A4 (fr)
JP (4) JP6882205B2 (fr)
KR (2) KR102412690B1 (fr)
AU (1) AU2017215825B9 (fr)
MA (1) MA43977A (fr)
NZ (1) NZ745113A (fr)
RU (1) RU2727598C2 (fr)
TW (1) TWI791430B (fr)
UA (1) UA123403C2 (fr)
WO (1) WO2017135412A1 (fr)
ZA (1) ZA201805245B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43977A (fr) * 2016-02-05 2018-12-12 Taiho Pharmaceutical Co Ltd Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave
CA3150729A1 (fr) * 2019-09-11 2021-03-18 Inspirna, Inc. Methodes de traitement du cancer
TWI888447B (zh) 2019-12-13 2025-07-01 美商因思博納公司 金屬鹽及其用途
CN118879871B (zh) * 2024-09-27 2025-05-30 中国人民解放军总医院第三医学中心 一种肾癌预后标志物tymp及tymp抑制剂的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100424934B1 (ko) 1995-03-29 2004-07-27 다이호야쿠힌고교 가부시키가이샤 우라실유도체및이를함유하는항종양효과증강제및항종양제
US7799783B2 (en) * 2005-01-26 2010-09-21 Taiho Pharmaceutical Co., Ltd. Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP5576591B2 (ja) * 2005-01-26 2014-08-20 大鵬薬品工業株式会社 α，α，α−トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤
US9371380B2 (en) * 2011-08-16 2016-06-21 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer
KR101847252B1 (ko) * 2013-03-27 2018-04-09 다이호야쿠힌고교 가부시키가이샤 이리노테칸염산염 수화물을 함유하는 항종양제
AU2014266278B2 (en) 2013-05-17 2017-07-13 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of TK1 protein has increased
CN106333952A (zh) 2014-02-19 2017-01-18 齐鲁制药有限公司 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法
MA43977A (fr) * 2016-02-05 2018-12-12 Taiho Pharmaceutical Co Ltd Méthode de traitement de patients atteints de cancer souffrant d'insuffisance rénale grave

Also Published As

Publication number Publication date
KR20210111348A (ko) 2021-09-10
NZ745113A (en) 2021-12-24
TWI791430B (zh) 2023-02-11
EP3412295A4 (fr) 2019-09-25
JP2025013684A (ja) 2025-01-24
US10456399B2 (en) 2019-10-29
WO2017135412A1 (fr) 2017-08-10
AU2017215825B9 (en) 2020-11-26
RU2018131573A (ru) 2020-03-05
AU2017215825B2 (en) 2020-09-10
US20200030329A1 (en) 2020-01-30
JP2023065622A (ja) 2023-05-12
JP2021113228A (ja) 2021-08-05
JP6882205B2 (ja) 2021-06-02
US10960004B2 (en) 2021-03-30
RU2018131573A3 (fr) 2020-03-05
AU2017215825A1 (en) 2018-08-23
KR102412690B1 (ko) 2022-06-23
KR102298144B1 (ko) 2021-09-03
US20210177850A1 (en) 2021-06-17
KR20180104744A (ko) 2018-09-21
UA123403C2 (uk) 2021-03-31
ZA201805245B (en) 2019-10-30
JPWO2017135412A1 (ja) 2018-12-06
EP3412295A1 (fr) 2018-12-12
RU2727598C2 (ru) 2020-07-22
TW201728328A (zh) 2017-08-16
US20240148730A1 (en) 2024-05-09
US20180338976A1 (en) 2018-11-29

Similar Documents

Publication Publication Date Title
EP3488001A4 (fr) Traitement du cancer
EP3813808A4 (fr) Méthodes de traitement de la toxicomanie
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
EP3452166A4 (fr) Stimulation intranasale pour le traitement de la maladie de la glande de meibomius et de la blépharite
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
IL252361A0 (en) Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
MA43374A (fr) Méthodes de traitement de tumeurs malignes
EP3448263A4 (fr) Traitement électrothérapeutique
EP3285773A4 (fr) Polythérapie pour le traitement du cancer
IL258521B1 (en) Combination therapy for the treatment of cancer
EP3463461A4 (fr) Procédés de traitement de la myasthénie grave généralisée réfractaire
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
PT3458052T (pt) Tratamento combinado do cancro
MA46361A (fr) Traitement du cancer de la prostate
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
SI3773558T1 (sl) Kombinirano zdravljenje artritične bolezni
EP3766497A4 (fr) Médicament pour le traitement de la toux
IL282232A (en) Diagnostic and therapeutic methods for sarcomatoid kidney cancer
LT3576740T (lt) Vėžio gydymas
MA52627A (fr) Traitement du cancer
MA53903A (fr) Méthode de traitement de la myasthénie grave
JOP20190056A1 (ar) طرق لعلاج إصابة كلى حادة
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EP3862000A4 (fr) Médicament de traitement de la toux chronique
EP3471722A4 (fr) Composés et méthodes pour la prévention et/ou le traitement du cancer